Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03842696 · ClinicalTrials.gov registry record · Phase 1

Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

A Phase 1 study of Myelodysplastic Syndromes and Diffuse Large B Cell Lymphoma, sponsored by University of Michigan Rogel Cancer Center.

Active
Registry status
Phase 1
Development phase
43
Enrollment target
7
Study locations

NCT03842696 is a Phase 1 study of Myelodysplastic Syndromes and Diffuse Large B Cell Lymphoma that is active but no longer recruiting, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 43 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (85% lower). The trial reports 7 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03842696, a Phase 1 study of Myelodysplastic Syndromes and Diffuse Large B Cell Lymphoma, is active but no longer recruiting, sponsored by University of Michigan Rogel Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
43 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this study is to determine the recommended phase 2 dose of the drug Vorinostat in children, adolescents and young adults following allogeneic blood or marrow transplant (BMT) and determine whether the addition of Vorinostat to the standard graft versus host disease (GVHD) prophylaxis will reduce the incidence of GVHD.

Conditions Studied

Myelodysplastic Syndromes Diffuse Large B Cell Lymphoma Non-Hodgkin Lymphoma Mantle Cell Lymphoma Follicular Lymphoma Hematologic Diseases Chronic Myelogenous Leukemia - Chronic Phase Acute Leukemia in Remission Chronic Myelogenous Leukemia, Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase

Interventions

  • DRUG Vorinostat
  • DRUG Methotrexate
  • DRUG Mycophenolate Mofetil (MMF)
  • PROCEDURE Blood and Marrow Transplant (BMT)
  • DRUG Tacrolimus (or cyclosporine)

Study Locations (7)

Michigan

  • University of Michigan Health System - Ann Arbor
  • Henry Ford Hospital - Detroit

Colorado

  • University of Colorado - Aurora

Georgia

  • Emory University - Atlanta

Indiana

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis

Tennessee

  • Vanderbilt-Ingram Cancer Center - Nashville

Wisconsin

  • Medical College of Wisconsin - Milwaukee

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2020-02-04
Est. Completion 2026-04-01
Phase Phase 1

Sponsor

University of Michigan Rogel Cancer Center

292 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03842696

The ClinicalTrials.gov registry entry for NCT03842696 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (85% lower). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 5 interventions - of which Vorinostat is the first listed.

NCT03842696 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Michigan, Colorado, Georgia.

Frequently Asked Questions

What is clinical trial NCT03842696 about?

NCT03842696 is a clinical study titled "Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation". The purpose of this study is to determine the recommended phase 2 dose of the drug Vorinostat in children, adolescents and young adults following allogeneic blood or marrow transplant (BMT) and determine whether the addition of Vorinostat to the standard graft versus host disease (GVHD) prophylaxis ...

What is the current status of trial NCT03842696?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2020-02-04. Estimated completion is 2026-04-01.

What conditions does trial NCT03842696 study?

This clinical trial studies the following conditions: Myelodysplastic Syndromes, Diffuse Large B Cell Lymphoma, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma.

What interventions are being tested in trial NCT03842696?

The interventions under investigation include: Vorinostat (DRUG), Methotrexate (DRUG), Mycophenolate Mofetil (MMF) (DRUG), Blood and Marrow Transplant (BMT) (PROCEDURE), Tacrolimus (or cyclosporine) (DRUG).

Who is sponsoring clinical trial NCT03842696?

This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03842696 being conducted?

This trial has 7 study locations across Colorado, Georgia, Indiana, Michigan, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Myelodysplastic Syndromes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Myelodysplastic Syndromes

All registered trials for this condition

Diffuse Large B Cell Lymphoma

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.